Shockwave Appoints Hajime Tada as General Counsel
June 10 2019 - 8:00AM
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the
development and commercialization of Intravascular Lithotripsy
(IVL) to treat complex calcified cardiovascular disease, announced
today that the Company has appointed Hajime Tada as General
Counsel.
From 2017 to 2019, Mr. Tada was General Counsel and Corporate
Secretary at LakePharma, Inc., a leading contract research
organization specializing in biologics services and
technology. Prior to LakePharma, Mr. Tada spent sixteen years
with Agilent Technologies, where he worked his way from Corporate
Counsel to Director of Litigation, Vice President and Deputy
General Counsel, and ultimately Acting General Counsel. During his
time at Agilent, Mr. Tada worked with the Company on a full range
of activities that spanned the globe and across subject matters,
including corporate governance, acquisitions and divestitures,
compliance, sales support, regulatory, intellectual property
strategy and litigation.
“We are pleased to welcome Haj as our new General Counsel,” said
Doug Godshall, President and Chief Executive Officer
of Shockwave Medical. “His extensive experience across the spectrum
of legal specialties makes Haj an exceptional addition to the team
that will enable us to work more effectively and augment our growth
trajectory.”
Mr. Tada holds a Bachelor of Arts in Political Science from Yale
University and a Juris Doctor from the New York University School
of Law.
About Shockwave Medical, Inc. Shockwave Medical
is focused on developing and commercializing products intended to
transform the way calcified cardiovascular disease is treated by
establishing a new standard of care with Intravascular Lithotripsy
(IVL). The company’s differentiated and proprietary IVL approach to
calcium modification uses sonic pressure waves to safely and
effectively fracture problematic calcium throughout the
cardiovascular system in a wide and growing number of applications.
For more information, visit www.shockwavemedical.com.
Caution Regarding Forward-Looking
StatementsThis press release may contain forward-looking
statements regarding Shockwave’s current expectations. Words such
as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,”
“project,” “plan,” “intend” or similar expressions, or statements
regarding intent, belief, or current expectations are
forward-looking statements. These statements are not guarantees of
future performance and are subject to certain risks, uncertainties
and assumptions that are difficult to predict. Factors that could
cause actual results to differ include, but are not limited to,
those described more fully in the section captioned “Risk Factors”
in the final prospectus related to the public offering filed with
the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Shockwave undertakes no duty to update such information except as
required under applicable law.
Media Contact: Scott Shadiow
+1.317.432.9210sshadiow@shockwavemedical.com
Investor Contact:Debbie Kaster, Gilmartin
Groupinvestors@shockwavemedical.com
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Apr 2023 to Apr 2024